Topical Nicotinamide in Combination with Calcipotriol for the Treatment of Mild to Moderate Psoriasis: A Double-Blinded, Randomized, Comparative Study
Background: Current treatment strategies of psoriasis are not completely satisfactorily. By inhibiting inflammatory cytokines, nicotinamide may enhance the effects of current topical treatments. We investigated whether the combination of topical calcipotriol and nicotinamide is more effective than c...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | fas |
Published: |
Vesnu Publications
2015-02-01
|
Series: | مجله دانشکده پزشکی اصفهان |
Subjects: | |
Online Access: | http://jims.mui.ac.ir/index.php/jims/article/view/4852 |
id |
doaj-04b7ea4d1d4949ea931beb5adfc33451 |
---|---|
record_format |
Article |
spelling |
doaj-04b7ea4d1d4949ea931beb5adfc334512020-11-25T00:42:00ZfasVesnu Publications مجله دانشکده پزشکی اصفهان1027-75951735-854X2015-02-0132314220222091761Topical Nicotinamide in Combination with Calcipotriol for the Treatment of Mild to Moderate Psoriasis: A Double-Blinded, Randomized, Comparative StudyAmir Hossein Siadat0Fariba Iraji1Mehdi Khodadadi2Maryam Kalateh-Jary3Mohammad Ali Nilforoushzadeh4Assistant Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran AND Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranProfessor, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranSkin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, IranSkin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, IranAssociate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, IranBackground: Current treatment strategies of psoriasis are not completely satisfactorily. By inhibiting inflammatory cytokines, nicotinamide may enhance the effects of current topical treatments. We investigated whether the combination of topical calcipotriol and nicotinamide is more effective than calcipotriol alone in treatment of psoriasis. Methods: Adult patients with mild to moderate psoriasis were randomized to receive topical calcipotriol 0.005% and nicotinamide 4% in combination or calcipotriol 0.005% alone, twice daily for 12 weeks. Patients were visited by a dermatologist at baseline and then, after the first and third months of therapy; and psoriasis severity was evaluated using the modified psoriasis area and severity index (PASI). Also, patient’s satisfaction was evaluated at the end of the trial using a 10-point rating scale. Findings: Sixty five patients (35 men) with the mean age of 36.5 ± 8.5 years completed the trial. Lesions on both sides were similar regarding baseline PASI score. At the end of the trial, PASI score was more reduced with calcipotriol + nicotinamide (83.6 ± 7.9 percent) compared to calcipotriol alone (77.8 ± 9.7 percent) (P < 0.001). Patients were also more satisfied with the improvement of lesions with calcipotriol + nicotinamide compared to calcipotriol alone (P < 0.001). Side effects included mild erythema and pruritus (4.6%) and moderate burning and sensitivity to light (3.0%). Conclusion: Nicotinamide can enhance the efficacy of calcipotriol when used in combination for topical psoriasis treatment, and it may be a good adjuvant to the current treatment regimens of psoriasis.http://jims.mui.ac.ir/index.php/jims/article/view/4852CalcipotrieneCalcipotriolNicotinamidePsoriasisTherapy |
collection |
DOAJ |
language |
fas |
format |
Article |
sources |
DOAJ |
author |
Amir Hossein Siadat Fariba Iraji Mehdi Khodadadi Maryam Kalateh-Jary Mohammad Ali Nilforoushzadeh |
spellingShingle |
Amir Hossein Siadat Fariba Iraji Mehdi Khodadadi Maryam Kalateh-Jary Mohammad Ali Nilforoushzadeh Topical Nicotinamide in Combination with Calcipotriol for the Treatment of Mild to Moderate Psoriasis: A Double-Blinded, Randomized, Comparative Study مجله دانشکده پزشکی اصفهان Calcipotriene Calcipotriol Nicotinamide Psoriasis Therapy |
author_facet |
Amir Hossein Siadat Fariba Iraji Mehdi Khodadadi Maryam Kalateh-Jary Mohammad Ali Nilforoushzadeh |
author_sort |
Amir Hossein Siadat |
title |
Topical Nicotinamide in Combination with Calcipotriol for the Treatment of Mild to Moderate Psoriasis: A Double-Blinded, Randomized, Comparative Study |
title_short |
Topical Nicotinamide in Combination with Calcipotriol for the Treatment of Mild to Moderate Psoriasis: A Double-Blinded, Randomized, Comparative Study |
title_full |
Topical Nicotinamide in Combination with Calcipotriol for the Treatment of Mild to Moderate Psoriasis: A Double-Blinded, Randomized, Comparative Study |
title_fullStr |
Topical Nicotinamide in Combination with Calcipotriol for the Treatment of Mild to Moderate Psoriasis: A Double-Blinded, Randomized, Comparative Study |
title_full_unstemmed |
Topical Nicotinamide in Combination with Calcipotriol for the Treatment of Mild to Moderate Psoriasis: A Double-Blinded, Randomized, Comparative Study |
title_sort |
topical nicotinamide in combination with calcipotriol for the treatment of mild to moderate psoriasis: a double-blinded, randomized, comparative study |
publisher |
Vesnu Publications |
series |
مجله دانشکده پزشکی اصفهان |
issn |
1027-7595 1735-854X |
publishDate |
2015-02-01 |
description |
Background: Current treatment strategies of psoriasis are not completely satisfactorily. By inhibiting inflammatory cytokines, nicotinamide may enhance the effects of current topical treatments. We investigated whether the combination of topical calcipotriol and nicotinamide is more effective than calcipotriol alone in treatment of psoriasis.
Methods: Adult patients with mild to moderate psoriasis were randomized to receive topical calcipotriol 0.005% and nicotinamide 4% in combination or calcipotriol 0.005% alone, twice daily for 12 weeks. Patients were visited by a dermatologist at baseline and then, after the first and third months of therapy; and psoriasis severity was evaluated using the modified psoriasis area and severity index (PASI). Also, patient’s satisfaction was evaluated at the end of the trial using a 10-point rating scale.
Findings: Sixty five patients (35 men) with the mean age of 36.5 ± 8.5 years completed the trial. Lesions on both sides were similar regarding baseline PASI score. At the end of the trial, PASI score was more reduced with calcipotriol + nicotinamide (83.6 ± 7.9 percent) compared to calcipotriol alone (77.8 ± 9.7 percent) (P < 0.001). Patients were also more satisfied with the improvement of lesions with calcipotriol + nicotinamide compared to calcipotriol alone (P < 0.001). Side effects included mild erythema and pruritus (4.6%) and moderate burning and sensitivity to light (3.0%).
Conclusion: Nicotinamide can enhance the efficacy of calcipotriol when used in combination for topical psoriasis treatment, and it may be a good adjuvant to the current treatment regimens of psoriasis. |
topic |
Calcipotriene Calcipotriol Nicotinamide Psoriasis Therapy |
url |
http://jims.mui.ac.ir/index.php/jims/article/view/4852 |
work_keys_str_mv |
AT amirhosseinsiadat topicalnicotinamideincombinationwithcalcipotriolforthetreatmentofmildtomoderatepsoriasisadoubleblindedrandomizedcomparativestudy AT faribairaji topicalnicotinamideincombinationwithcalcipotriolforthetreatmentofmildtomoderatepsoriasisadoubleblindedrandomizedcomparativestudy AT mehdikhodadadi topicalnicotinamideincombinationwithcalcipotriolforthetreatmentofmildtomoderatepsoriasisadoubleblindedrandomizedcomparativestudy AT maryamkalatehjary topicalnicotinamideincombinationwithcalcipotriolforthetreatmentofmildtomoderatepsoriasisadoubleblindedrandomizedcomparativestudy AT mohammadalinilforoushzadeh topicalnicotinamideincombinationwithcalcipotriolforthetreatmentofmildtomoderatepsoriasisadoubleblindedrandomizedcomparativestudy |
_version_ |
1725284357441060864 |